FDA approves Teva’s fentanyl transdermal system patches
NORTH WALES, Pa The Food and Drug Administration has approved Teva Pharmaceuticals’ fentanyl transdermal system, CII, Teva announced Thursday.
The drug is available as a patch with dosages of 25 micrograms, 50 micrograms, 75 micrograms and 100 micrograms in cartons containing five patches. It is a generic equivalent to Johnson & Johnson’s Duragesic Transdermal System. Mylan also markets a generic version of the patches.
“Our customers count on Teva for a continuous supply of new generic products,” Teva vice president for sales and marketing John Denman said. “With the launch of fentanyl transdermal system, we add another quality product to our broad line of affordable generic pharmaceuticals.”
Nerviano partners with Genentech to develop anticancer drugs
NEW YORK A company that develops cancer drugs has announced a multi-year collaboration with Genentech.
Nerviano Medical Sciences said that it would collaborate with South San Francisco, Calif.-based Genentech to search for antibody drug compounds to develop anticancer drugs. It is the second agreement between Genentech and NMS in less than a year, NMS said.
Genentech will have exclusive rights to fully develop and commercialize licensed products, while NMS will primarily synthesize and manufacture drug reagents.
More Americans cutting back on prescription medications
NEW YORK Economic difficulties are causing more Americans to forego prescription drugs, according to The New York Times.
Costs for housing and food are trumping costs for drugs, and some patients have stopped taking drugs for chronic conditions such as osteoporosis and high cholesterol. Some drug makers have reported decreases in sales of certain drugs, while IMS Health has reported reductions in prescriptions being dispensed.
The Times reported that the trend could cause increases in complications from chronic disease.